TenSixteen Bio
TenSixteen Bio is a San Francisco-based clinical-stage biotechnology company pioneering the study of somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics for age-related diseases including cancer and cardiovascular disease. Founded by CEO Mark Chao and launched in 2022 with a $40M Series A from Foresite Capital and GV (formerly Google Ventures), the company combines human genetics, functional genomics and next-generation-sequencing (NGS) based assays to identify CHIP-linked mutations and translate them into companion diagnostics and precision-medicine treatments. This profile was added to the API Evangelist network as a portfolio-company lead; as a therapeutics and diagnostics company it publishes no public developer API surface.
TenSixteen Bio is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Precision Medicine, and Genomics.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 3
The organization behind the API